

Targeted *PCSK9* genome editing in embryos by CRISPR-Cas9 system

One Sentence Summary: The efficacy and safety of our *in vitro* and *in vivo* studies presented here suggest that targeted *PCSK9* genome editing in embryos by CRISPR-Cas9 system provides a potential strategy for the prevention and treatment of familial hypercholesterolemia and coronary heart disease.

Feifei Cheng¹, Kaijing Chen¹, Xiaoqing Zhou¹, Shuo Song¹, Jinzhou Qin², Yangran Chen¹, Rui Chen¹, Dikai Zhang³, Chenglu Qin⁴, Chenyang Si⁵, Zhijian Wang⁶, Dayong Hao⁷, Renli Zhang⁸, Michael W. Deem^{9,10,11}, Jiankui He^{1,*}

¹Department of Biology, South University of Science and Technology of China, Shenzhen 518055, China.

²Department of Human Reproductive Medicine Center, Third Affiliated Hospital of Shenzhen University, Shenzhen 518001, China.

³Department of Gynecology, Department of Human Reproductive Medicine Center, Third Affiliated Hospital of Shenzhen University, Shenzhen 518001, China.

⁴Department of Obstetrics, Third Affiliated Hospital of Shenzhen University, Shenzhen 518001, China.

⁵Yunnan Key Laboratory of Primate Biomedicine Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming 650500, China.

⁶Department of Cardiovasology, Peking University Shenzhen Hospital, Shenzhen 518036, China.